(44- 20) 74 18 84 00 Fax (44- 20) 74 18 86 68 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Hvilke konsekvenser har afslaget for patienter, der deltager i kliniske undersøgelser med Zelnorm?
©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Le CHMP estimait que les bénéfices de Zelnorm ne sont pas supérieurs aux risques qu’ il comporte.